287 related articles for article (PubMed ID: 20876420)
1. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.
Liu M; Wang L; Bongartz T; Hawse JR; Markovic SN; Schaid DJ; Mushiroda T; Kubo M; Nakamura Y; Kamatani N; Goss PE; Ingle JN; Weinshilboum RM
Breast Cancer Res; 2012 Mar; 14(2):R41. PubMed ID: 22405131
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Ingle JN
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S17. PubMed ID: 21172079
[No Abstract] [Full Text] [Related]
4. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
Liu M; Goss PE; Ingle JN; Kubo M; Furukawa Y; Batzler A; Jenkins GD; Carlson EE; Nakamura Y; Schaid DJ; Chapman JA; Shepherd LE; Ellis MJ; Khosla S; Wang L; Weinshilboum RM
Mol Endocrinol; 2014 Oct; 28(10):1740-51. PubMed ID: 25148458
[TBL] [Abstract][Full Text] [Related]
6. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract][Full Text] [Related]
9. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
Ho MF; Bongartz T; Liu M; Kalari KR; Goss PE; Shepherd LE; Goetz MP; Kubo M; Ingle JN; Wang L; Weinshilboum RM
Mol Endocrinol; 2016 Mar; 30(3):382-98. PubMed ID: 26866883
[TBL] [Abstract][Full Text] [Related]
10. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
11.
Ho MF; Ingle JN; Bongartz T; Kalari KR; Goss PE; Shepherd LE; Mushiroda T; Kubo M; Wang L; Weinshilboum RM
Mol Pharmacol; 2017 Aug; 92(2):175-184. PubMed ID: 28615284
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
13. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
Ingle JN; Kalari KR; Momozawa Y; Kubo M; Furukawa Y; Shepherd LE; Ellis MJ; Goss PE; Barman P; Carlson EE; Sinnwell JP; Tang X; Goetz MP; Chen BE; Cairns J; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2019 Oct; 29(8):183-191. PubMed ID: 31211741
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Winters L; Habin K; Gallagher J
Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
17. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
18. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
Ingle JN; Cairns J; Suman VJ; Shepherd LE; Fasching PA; Hoskin TL; Singh RJ; Desta Z; Kalari KR; Ellis MJ; Goss PE; Chen BE; Volz B; Barman P; Carlson EE; Haddad T; Goetz MP; Goodnature B; Cuellar ME; Walters MA; Correia C; Kaufmann SH; Weinshilboum RM; Wang L
Clin Cancer Res; 2020 Jun; 26(12):2986-2996. PubMed ID: 32098767
[TBL] [Abstract][Full Text] [Related]
20. RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.
Wang J; Lu K; Song Y; Zhao S; Ma W; Xuan Q; Tang D; Zhao H; Liu L; Zhang Q
PLoS One; 2015; 10(7):e0133964. PubMed ID: 26218592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
